Cytomegalovirus Clinical Trials

8 recruiting

Cytomegalovirus Trials at a Glance

46 actively recruiting trials for cytomegalovirus are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Suzhou, Tianjin, and Paris. Lead sponsors running cytomegalovirus studies include Takeda, Assistance Publique - Hôpitaux de Paris, and The First Affiliated Hospital of Soochow University.

Browse cytomegalovirus trials by phase

Treatments under study

About Cytomegalovirus Clinical Trials

Looking for clinical trials for Cytomegalovirus? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cytomegalovirus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cytomegalovirus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 46 trials

Recruiting
Phase 1

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases (NIAID)12 enrolled10 locationsNCT06118515
Recruiting
Phase 1

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Cytomegalovirus Prophylaxis
Merck Sharp & Dohme LLC40 enrolled12 locationsNCT07199465
Recruiting
Early Phase 1

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Allogeneic Hematopoietic Stem Cell Transplantation RecipientAdenovirusCytomegalovirus+2 more
Sumithira Vasu20 enrolled2 locationsNCT03665675
Recruiting
Phase 2

Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)

Cytomegalovirus Viraemia
Murdoch Childrens Research Institute232 enrolled7 locationsNCT06574789
Recruiting
Phase 3

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

Kidney Transplant; ComplicationsKidney DiseasesCytomegalovirus (CMV)
University of California, San Francisco360 enrolled5 locationsNCT06798909
Recruiting

Breakthrough CMV Lung Transplant -Multicentre

Cytomegalovirus Infections
University of Alberta40 enrolled1 locationNCT04439916
Recruiting

Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.

Human Cytomegalovirus (HCMV)
Fondazione IRCCS Policlinico San Matteo di Pavia90 enrolled1 locationNCT07477925
Recruiting
Phase 3

A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Cytomegalovirus (CMV)
Takeda20 enrolled12 locationsNCT06439342
Recruiting
Phase 2

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

AdenovirusCytomegalovirus
St. Jude Children's Research Hospital42 enrolled1 locationNCT05664126
Recruiting
Not Applicable

Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

Cytomegalovirus InfectionsCMV
The First Affiliated Hospital of Soochow University330 enrolled1 locationNCT06812598
Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Streptococcus PneumoniaeMalariaMeningitis+55 more
Institut Pasteur du Cambodge10,000 enrolled1 locationNCT07358910
Recruiting
Phase 4

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Kidney Transplant; ComplicationsCytomegalovirusOrgan Transplant
Camille N. Kotton, MD80 enrolled2 locationsNCT06958796
Recruiting
Not Applicable

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Kidney Transplantation, Cytomegalovirus InfectionsEBV InfectionAntiviral Prophylaxis
National Taiwan University Hospital80 enrolled1 locationNCT07294547
Recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

Kidney DiseaseCytomegalovirus (CMV)Kidney Failure
Takeda10 enrolled25 locationsNCT06243731
Recruiting
Phase 2

Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies

Cytomegalovirus (CMV)
Seoul National University Hospital20 enrolled1 locationNCT07014319
Recruiting

A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

Cytomegalovirus (CMV)
Takeda168 enrolled1 locationNCT06555432
Recruiting
Not Applicable

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Hematopoietic Cell TransplantCytomegalovirus Cell Mediated Immunity
M.D. Anderson Cancer Center105 enrolled1 locationNCT06639854
Recruiting
Early Phase 1

T Cell Therapy of Opportunistic Cytomegalovirus Infection

Hematopoietic Stem Cell TransplantCytomegalovirus InfectionsOpportunistic Infections
Mari Dallas20 enrolled1 locationNCT02982902
Recruiting
Phase 3

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant
University of Wisconsin, Madison90 enrolled1 locationNCT06407232
Recruiting

A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection

Cytomegalovirus (CMV)
Takeda250 enrolled1 locationNCT06577363